33 results about "Her2 receptor" patented technology

The present invention relates to a method of diagnosis and therapy of cancers expressing the HER2 receptor.The invention provides antibodies or fragments thereof that recognizes an epitope of a HER2 receptor truncated form, said epitope being defined by a sequence included in SEQ ID NO: 2.The invention also provides a method of cancer diagnosis, which comprises the detection of the presence of the HER2 receptor truncated form consisting of the amino acid sequence SEQ ID NO: 1 in a patient sample.

The present invention relates to a method of diagnosis and therapy of cancers expressing the HER2 receptor.The invention provides antibodies or fragments thereof that recognise an epitope of the HER2 receptor truncated form CTF-611, said epitope being defined by a sequence included in SEQ ID NO: 2, and that are capable of discriminating between CTF-611 and CTF-616 (represented by SEQ ID NO:7), preferably additionally capable of discriminating between CTF-611 and CTF-613 (represented by SEQ ID NO:6).The invention also provides a method of cancer diagnosis using the disclosed antibodies, which comprises the detection of the presence of the HER2 receptor truncated form consisting of the amino acid sequence SEQ ID NO: 1 in a patient sample.

The present invention relates to anti-HER2 binding molecules (e.g., antibodies and antigen binding fragments thereof), derived HER2-binding molecules (e.g., bispecific anti-HER2 antibodies), and antibody-drug conjugates (ADC) that bind the extracellular domain of the HER2 receptor. Also provided are pharmaceutical formulation comprising the disclosed compositions and method for the treating diseases associated with HER2-mediated signal transduction.

Methods for treating a subject with a cancer that is characterized by overexpression of HER2 receptor protein using a combination of interleukin-2 (IL-2) or variant thereof and at least one anti-HER2 antibody or fragment thereof are provided. These anti-tumor agents are administered as two separate pharmaceutical compositions, one containing IL-2 (or variant thereof), the other containing at least one anti-HER2 antibody (or fragment thereof), according to a dosing regimen. Administering of these two agents together potentiates the effectiveness of the anti-HER2 antibody alone, resulting in a positive therapeutic response that is improved with respect to that observed with this anti-tumor agent.

The present invention provides a single chain fragment antibody-polypeptide fusion protein and applications thereof, the protein is a fusion protein which can be combined with Her2 receptors and can carry anti-cancer siRNA drug, and the fusion protein can serve as the vector of the anti-cancer siRNA drug. The single chain fragment antibody is Her2-ScFv, and the polypeptide is nucleoprotamine fragment polypeptide. The sequence of the single chain fragment antibody-polypeptide fusion protein is shown as SEQ ID NO.1. The Her2 single chain fragment antibody and the nucleoprotamine polypeptide fusion protein, which are constructed by the present invention, can be combined with Her2 receptors and can carry the anti-cancer siRNA drug. The fusion protein of the present invention can directionallyintroduce the anti-cancer siRNA drug into target cancer cells, and a non-viral vector tool is developed to speed up the application of the RNAi technology in clinic.

The related chalketoxime shown as the formula (1) is prepared by heating and reflux reacting the 2', 4'-dihydroxy -6'-methoxyl-3', 5'-dimethylchalcone and hydroxylamine hydrochloride in pyridine, which has well solvability, fit to direct inject for drug, restrains obviously all of the activity of blood vessel endothelium growth factor receptor, HER2 receptor and Tyr kinase as PDGFR receptor, the external growth of cells for breast cancer and liver cancer, and the phosphorylation of KDR in ECV304 cell, HER2 in MDA-MB-453 cell and PDGFR receptor in C6 cell, and benefit to treat tumor.

The invention relates to the use of an EGFR / HER2 receptor tyrosine kinase inhibitor in the preparation of medicines for treating cancer. Specifically, the present invention relates to the use of a compound represented by the EGFR / HER2 receptor tyrosine kinase inhibitor formula (I) in the preparation of a drug for treating anti-HER2 drug-resistant cancer.

The invention discloses chimeric antigen receptor and induced apoptosis enzyme co-fused compound protein, a coding sequence thereof and modified T lymphocyte containing the compound protein. The invention also relates to application of the above compound protein and the modified T lymphocyte in prevention and treatment of breast cancer. The constructed specific chimeric antigen receptor and induced apoptosis enzyme co-fused compound protein has functions of binding to a Her2 receptor, enhancing activated state of T lymphocyte and regulating cell apoptosis. The modified T lymphocyte can efficiently kill Her-2 positive breast cancer cells and can induce modified T lymphocyte apoptosis under the action of the drug AP1903 to terminate the expanding killing effect as a safety guarantee.

The invention belongs to the field of radiopharmaceuticals and nuclear medicine, and particularly relates to an 18F marked affinity compound and a preparation method and application thereof. On the one hand, the uptake value of tumors on the 18F marked affinity compound is high, and tumor development sensitivity is high; on the other hand, the uptake value of the liver on the 18F marked affinity compound is low, and toxic and side effects on the liver are small. Animal experiments indicate that the uptake value of tumors on the 18F marked affinity compound is high, the residence time is short, the target / target-to-nontarget ratio is high, good pharmacokinetics characteristics are achieved, the biological properties are good, and the compound can be directly used as a tumor PET photographic developer targeted to an HER2 receptor. The preparation method of the 18F marked affinity compound is low in cost, easy and fast to operate, high in labeling rate and high in radiochemical purity of labeled products, and the prepared 18F marked affinity compound can be clinically applied and popularized as the tumor PET photographic developer targeted to the HER2 receptor.

The invention belongs to the field of radiopharmaceuticals, and particularly relates to an 18-labeling affinity type compound and a preparation method and application thereof. On one hand, the absorbing value of a tumor to the 18-labeling affinity type compound is high, and the tumor development sensitivity high; on the other hand, the absorbing value of the liver to the 18-labeling affinity type compound is low, and the toxic and side effect on the liver is little. Animal experiments show that the 18-labeling affinity type compound can serve as tumor PET photographic developer targeting an HER2 receiver due to the fact that the absorbing value of the tumor to the 18-labeling affinity type compound is high, the residence time is short, the target ratio / target-to-nontarget ratio is high, good pharmacokinetics characters are achieved, and the biological performance is excellent. The preparation method is low in cost, and easy, convenient and quick to operate, the labeling rate is high, the radiochemical purity of a labeled product is high, and the prepared 18-labeling affinity type compound serving as the tumor PET photographic developer tarting the HER2 receiver can be clinically applied and popularized easily.

The present invention provides a polypeptide compound with HER2 targeting function, which is composed of a HER2 affinity body and a bifunctional chelating agent connected through a polypeptide sequence; the polypeptide sequence is Met-Val-Lys; the polypeptide compound has a general structure The formula is shown in the following formula (I), wherein, R is a HER2 affinity body molecule, and X is a bifunctional chelating agent group. The present invention also provides a HER2-targeted radiolabeled complex using the polypeptide compound as a ligand. The radiolabeled complexes of the present invention can be used as radioactive diagnostic probes for the evaluation of HER2 receptors in breast cancer. The probes can reduce kidney accumulation while keeping tumor uptake unchanged, thereby improving tumor target and HER2 receptors. Non-target ratio, while reducing the radiation dose to the kidney. The present invention also provides the preparation method of the polypeptide compound and radiolabeled complex, and its application in the preparation of HER2-positive breast cancer radiodiagnostic and therapeutic probes for humans or animals.

The invention relates to application of an EGFR / HER2 inhibitor combined with a pyrimidine antimetabolic drug, in particular to application of an EGFR / HER2 receptor tyrosine kinase inhibitor combined with a pyrimidine antimetabolic drug in preparation of drugs for treating cancers.